Overview of interleukin-2 function, production and clinical applications

被引：354

作者：

Gaffen, SL

Liu, KD

机构：

[1] SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14214 USA

[2] SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA

[3] Univ Calif San Francisco, Dept Med, Div Nephrol & Crit Care Med, San Francisco, CA 94143 USA

来源：

CYTOKINE | 2004年 / 28卷 / 03期

关键词：

D O I：

10.1016/j.cyto.2004.06.010

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The existence of interleukin (IL)-2 has been recognized for over 25 years, and it remains one of the most extensively studied cytokines. Here we present a broad overview of IL-2 history, functional activities, biological sources, regulation and applications to disease treatment. IL-2 exerts a wide spectrum of effects on the immune system, and it plays crucial roles in regulating both immune activation and homeostasis. Both IL-2 and its multipartite receptor are prototypical of the Type I receptor superfamily, and both have been exploited in numerous ways in the clinic. Despite the wealth of information generated about IL-2 from in vitro culture systems, in vivo mouse knockout models, and clinical trials in humans, fascinating new aspects of its functions in the immune system continue to emerge. (C) 2004 Elsevier Ltd. All rights reserved.

引用

收藏

页码：109 / 123

页数：15

相关论文

共 129 条

[1] Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor beta chain [J].

Adachi, M ;

Ishino, M ;

Torigoe, T ;

Minami, Y ;

Matozaki, T ;

Miyazaki, T ;

Taniguchi, T ;

Hinoda, Y ;

Imai, K .

ONCOGENE, 1997, 14 (13) :1629-1633

[2] Long-range transcriptional regulation of cytokine gene expression [J].

Agarwal, S ;

Rao, A .

CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (03) :345-352

[3] INFLAMMATION BUT NOT AUTOIMMUNITY OCCURS IN TRANSGENIC MICE EXPRESSING CONSTITUTIVE LEVELS OF INTERLEUKIN-2 IN ISLET BETA-CELLS [J].

ALLISON, J ;

MALCOLM, L ;

CHOSICH, N ;

MILLER, JFAP .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (05) :1115-1121

[4] EFFECTS OF ROUTE AND FORMULATION ON CLINICAL PHARMACOKINETICS OF INTERLEUKIN-2 [J].

ANDERSON, PM ;

SORENSON, MA .

CLINICAL PHARMACOKINETICS, 1994, 27 (01) :19-31

[5] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[6] The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T cell activation [J].

Attema, JL ;

Reeves, R ;

Murray, V ;

Levichkin, I ;

Temple, MD ;

Tremethick, DJ ;

Shannon, AF .

JOURNAL OF IMMUNOLOGY, 2002, 169 (05) :2466-2476

[7] IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS [J].

AUPHAN, N ;

DIDONATO, JA ;

ROSETTE, C ;

HELMBERG, A ;

KARIN, M .

SCIENCE, 1995, 270 (5234) :286-290

[8] LOW-DOSE INTERLEUKIN-2 PREVENTS THE DEVELOPMENT OF EPSTEIN-BARR-VIRUS (EBV)-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE IN SCID/SCID MICE RECONSTITUTED IP WITH EBV-SEROPOSITIVE HUMAN PERIPHERAL-BLOOD LYMPHOCYTES [J].

BAIOCCHI, RA ;

CALIGIURI, MA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) :5577-5581

[9] STRUCTURAL DESIGN AND MOLECULAR EVOLUTION OF A CYTOKINE RECEPTOR SUPERFAMILY [J].

BAZAN, JF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (18) :6934-6938

[10] UNRAVELING THE STRUCTURE OF IL-2 [J].

BAZAN, JF .

SCIENCE, 1992, 257 (5068) :410-412

← 1 2 3 4 5 6 7 8 9 10 →